Why shouldn't selumetinib be used in adults? Analysis of medication restrictions for children and adults

Selumetinib is a targeted treatment drug for neurofibromatosis. It is mainly used to treat children with neurofibromatosis (NF1). However, there are certain restrictions on the use of this drug in adults. First, the use of selumetinib has mainly been verified and approved through rigorous clinical trials in the pediatric population, especially for the treatment of neurofibromatosis. Due to the large physiological differences between adults and children, especially in terms of drug metabolism and immune response, the safety and efficacy of selumetinib in adults have not been fully verified. Therefore, there are greater risks in using this drug in adults.

The therapeutic efficacy and safety of selumetinib in children have been confirmed through clinical studies, and the drug has been approved in many countries for the treatment of children 6 years old and above. However, adults have different metabolic rates, body weight, organ function, and drug responses than children, which means that drugs may not be as effective as expected in adults and may cause more side effects. The drug metabolism pathways in adults are different from those in children, which may also lead to too high or too low drug concentrations in adults, thereby affecting efficacy and increasing toxicity.

As a targeted therapy drug, selumetinib's side effect spectrum may be closely related to the patient's age, physical condition, and other health conditions. In children, the side effects of selumetinib are relatively controllable, but in adults, because the adult population may have more underlying diseases or comorbidities, the side effects of the drug may be aggravated, leading to increased risks of treatment. Therefore, great caution must be used when using it in adults, especially when there is not sufficient clinical data to support it.

Existing drug guidelines and clinical practice recommendations emphasize that adults should give priority to drugs that have been validated and approved in adult populations, while the use of selumetinib is still mainly limited to children. As more clinical data accumulates, the indications for the use of selumetinib in adults may be further explored and studied in the future. However, at present, the adult population should not blindly use this drug, but should seek more appropriate treatment options.

Reference materials:https://www.koselugo.com